The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer. Constantin TA, Varela-Carver A, Greenland KK, de Almeida GS, et al. Br J Cancer 2023 Apr 19. doi: 10.1038/s41416-023-02252.

Read + Share

Amedeo Smart

Independent Medical Education

Constantin TA, Varela-Carver A, Greenland KK, de Almeida GS, et al. The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer. Br J Cancer 2023 Apr 19. doi: 10.1038/s41416-023-02252.
PMID: 37076563